Cardiac electrophysiology

Field Medical Announces First-in-Human Trials for Groundbreaking FieldForce™ Ventricular Pulsed Field Ablation Technology

Retrieved on: 
목요일, 5월 9, 2024
PFA, Physics, Safety, Arrhythmia, Catheter ablation, HRS, PVC, MD, Cardiac electrophysiology, Workflow, Mount Sinai Health System, Ventricular tachycardia, Cardiac cycle, Patient, Atrial fibrillation, Boston Scientific, Medical device

CARDIFF-BY-THE-SEA, Calif., May 9, 2024 /PRNewswire/ -- Field Medical,™ Inc., a pioneer in pulsed field cardiac catheter ablation technology, today announced the initiation of its first-in-human study for the FieldForce™ Ablation System at Na Homolce Hospital in Prague, Czech Republic. The Ventricular Catheter Ablation Study, VCAS, will enroll up to 60 patients at up to 5 sites world-wide. The VCAS investigational study is a critical step towards demonstrating safety and performance of the FieldForce™ Ablation System, developed specifically to address the limitations of existing pulsed field ablation (PFA) and radiofrequency (RF) ablation systems, including a more time efficient treatment protocol for the treatment of ventricular arrhythmias. Preliminary results will be presented on May 16, 2024, at the Heart Rhythm Scientific Sessions in Boston, Mass.

Key Points: 
  • First and only contact force pulsed field ablation (PFA) system designed to transform treatment for millions with life-threatening ventricular arrhythmias.
  • CARDIFF-BY-THE-SEA, Calif., May 9, 2024 /PRNewswire/ -- Field Medical,™ Inc., a pioneer in pulsed field cardiac catheter ablation technology, today announced the initiation of its first-in-human study for the FieldForce™ Ablation System at Na Homolce Hospital in Prague, Czech Republic.
  • The Ventricular Catheter Ablation Study, VCAS , will enroll up to 60 patients at up to 5 sites world-wide.
  • Current ventricular catheter ablation methods involve lengthy procedures and significant risks associated with thermal ablation, like conventional RF ablation.

Field Medical Announces First-in-Human Trials for Groundbreaking FieldForce™ Ventricular Pulsed Field Ablation Technology

Retrieved on: 
목요일, 5월 9, 2024
PFA, Physics, Safety, Arrhythmia, Catheter ablation, HRS, PVC, MD, Cardiac electrophysiology, Workflow, Mount Sinai Health System, Ventricular tachycardia, Cardiac cycle, Patient, Atrial fibrillation, Boston Scientific, Medical device

CARDIFF-BY-THE-SEA, Calif., May 9, 2024 /PRNewswire/ -- Field Medical,™ Inc., a pioneer in pulsed field cardiac catheter ablation technology, today announced the initiation of its first-in-human study for the FieldForce™ Ablation System at Na Homolce Hospital in Prague, Czech Republic. The Ventricular Catheter Ablation Study, VCAS, will enroll up to 60 patients at up to 5 sites world-wide. The VCAS investigational study is a critical step towards demonstrating safety and performance of the FieldForce™ Ablation System, developed specifically to address the limitations of existing pulsed field ablation (PFA) and radiofrequency (RF) ablation systems, including a more time efficient treatment protocol for the treatment of ventricular arrhythmias. Preliminary results will be presented on May 16, 2024, at the Heart Rhythm Scientific Sessions in Boston, Mass.

Key Points: 
  • First and only contact force pulsed field ablation (PFA) system designed to transform treatment for millions with life-threatening ventricular arrhythmias.
  • CARDIFF-BY-THE-SEA, Calif., May 9, 2024 /PRNewswire/ -- Field Medical,™ Inc., a pioneer in pulsed field cardiac catheter ablation technology, today announced the initiation of its first-in-human study for the FieldForce™ Ablation System at Na Homolce Hospital in Prague, Czech Republic.
  • The Ventricular Catheter Ablation Study, VCAS , will enroll up to 60 patients at up to 5 sites world-wide.
  • Current ventricular catheter ablation methods involve lengthy procedures and significant risks associated with thermal ablation, like conventional RF ablation.

MarinHealth Medical Center Becomes First Hospital in Northern California to Successfully Implant AVEIR™ DR, the World’s First Dual Chamber Leadless Pacemaker System

Retrieved on: 
금요일, 4월 5, 2024
Cardiology, Biotechnology, Surgery, General Health, Health, Medical Devices, Hospitals, Health Technology, VR, Communication, Infection, Atrial fibrillation, Risk, Immunosuppression, Patient, Cardiac electrophysiology, MD, Life, Stroke, Leg, Engineering, Heart, Dialysis, San Francisco Bay Area, FDA, Food, Medical device

MarinHealth Medical Center today announced the successful implantation of an AVEIR™ DR pacemaker system, becoming the first hospital in Northern California to insert the world’s first dual chamber leadless pacemaker system.

Key Points: 
  • MarinHealth Medical Center today announced the successful implantation of an AVEIR™ DR pacemaker system, becoming the first hospital in Northern California to insert the world’s first dual chamber leadless pacemaker system.
  • “MarinHealth is proud to be at the forefront in the clinical care of heart rhythm disorders.
  • Now, we are excited to become the first center in Northern California to offer dual chamber leadless pacemaker technology, which provides yet another state-of-the-art solution for heart rhythm patients in our community,” said Anita Chandrasena, MD , Chief Medical Officer of MarinHealth.
  • Roughly one-tenth the size of a traditional pacemaker, the dual chamber AVEIR leadless pacing system is made up of two devices: a ventricular (VR) and an atrial (AR) leadless pacemaker.

Texas Cardiac Arrhythmia Institute at St. David's Medical Center to host international conference on complex cardiac arrhythmias

Retrieved on: 
화요일, 3월 26, 2024
Arrhythmia, American Medical Association, St Davids, University of Pennsylvania, Mount Sinai Hospital, MedStar Health, Patient, PFA, Electrophysiology, University, LAA, Medical Center, Cleveland Clinic, Atrial fibrillation, Ventricular tachycardia, Physician, Cardiac electrophysiology, Vancouver General Hospital, PRA

AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on complex arrhythmias, EPLive 2024.

Key Points: 
  • AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on complex arrhythmias, EPLive 2024.
  • Live cases, which are broadcast with expert commentary from the state-of-the-art Electrophysiology Center at St. David's Medical Center, will serve as the primary teaching tool.
  • The Texas Cardiac Arrhythmia Institute features the leading robotic electrophysiology center in North America.
  • The 72,000-square-foot center, which opened in 2019, includes six electrophysiology labs equipped with advanced technology for treatment of complex arrhythmias.

Texas Cardiac Arrhythmia Institute at St. David's Medical Center to host international conference on complex cardiac arrhythmias

Retrieved on: 
화요일, 3월 26, 2024
Arrhythmia, American Medical Association, St Davids, University of Pennsylvania, Mount Sinai Hospital, MedStar Health, Patient, PFA, Electrophysiology, University, LAA, Medical Center, Cleveland Clinic, Atrial fibrillation, Ventricular tachycardia, Physician, Cardiac electrophysiology, Vancouver General Hospital, PRA

AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on complex arrhythmias, EPLive 2024.

Key Points: 
  • AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on complex arrhythmias, EPLive 2024.
  • Live cases, which are broadcast with expert commentary from the state-of-the-art Electrophysiology Center at St. David's Medical Center, will serve as the primary teaching tool.
  • The Texas Cardiac Arrhythmia Institute features the leading robotic electrophysiology center in North America.
  • The 72,000-square-foot center, which opened in 2019, includes six electrophysiology labs equipped with advanced technology for treatment of complex arrhythmias.

PrepMD and Magnifi Group Launch Annual EP Course for Fellows and Young Attendings

Retrieved on: 
금요일, 3월 22, 2024
Partnership, History, MD, EP, Wolpe, Cardiac electrophysiology, Nursing

BRAINTREE, Mass., March 22, 2024 /PRNewswire/ -- PrepMD, the leading provider of cardiac healthcare solutions, and Magnifi Group, Inc., renowned for its educational courses for Orthopedic Fellows, today announced partnership to create and manage an innovative annual Electrophysiology (EP) Fellows and Young EP Attendings course .

Key Points: 
  • BRAINTREE, Mass., March 22, 2024 /PRNewswire/ -- PrepMD, the leading provider of cardiac healthcare solutions, and Magnifi Group, Inc., renowned for its educational courses for Orthopedic Fellows, today announced partnership to create and manage an innovative annual Electrophysiology (EP) Fellows and Young EP Attendings course .
  • Renowned Electrophysiologist Vivek Reddy, MD will lead the course, supported by an estimated ten distinguished EP specialists.
  • Andrew Wolpe, President/COO of Magnifi Group, anticipates a promising launch of the EP Fellows Program with PrepMD's collaboration.
  • It is available to 2nd-year EP fellows and 1st and 2nd-year attendings, with limited spots for 55 attendees.

Methodist Le Bonheur Healthcare first in Tennessee to offer "paradigm-shifting" technology for AFib patients

Retrieved on: 
목요일, 3월 14, 2024
MLH, Le Bonheur Children's Hospital, Heat, Atrial fibrillation, Anesthesia, Patient, Methodist University Hospital, PFA, Medtronic, Freezing, Arrhythmia, Ventricular fibrillation, Methodism, Cardiac electrophysiology, Hospital

MEMPHIS, Tenn. , March 14, 2024 /PRNewswire/ -- Methodist Le Bonheur Healthcare is proud to announce it is the first healthcare system in Tennessee to offer the Medtronic PulseSelect™ Pulsed Field Ablation (PFA) technology to patients suffering from atrial fibrillation (AF).

Key Points: 
  • MEMPHIS, Tenn. , March 14, 2024 /PRNewswire/ -- Methodist Le Bonheur Healthcare is proud to announce it is the first healthcare system in Tennessee to offer the Medtronic PulseSelect™ Pulsed Field Ablation (PFA) technology to patients suffering from atrial fibrillation (AF).
  • "Pulsed Field Ablation is a paradigm-shifting technology," said Dr. Yehoshua Levine, division chief of cardiac electrophysiology at Methodist Le Bonheur Healthcare who performed the first PFA at Methodist University Hospital.
  • "PFA allows us to deliver timely treatment to more patients when they need help the most," said Dr. James Litzow, cardiac electrophysiologist with Methodist Le Bonheur Germantown Hospital.
  • Across the MLH system , the cardiovascular team at Methodist University Hospital conducted the first PFA for the healthcare system on March 11 with Methodist Le Bonheur Germantown Hospital's cardiovascular team conducting its first PFA on March 12.

St. Elizabeth Healthcare First in Kentucky to Implant New Device To Treat Abnormal Heart Rhythm

Retrieved on: 
금요일, 2월 16, 2024
Cardiac electrophysiology, EV, FDA, Cardiology, Food, Heart rate, Arrhythmia, Tachycardia, Vein, Heart failure, ATP, Medtronic, Heart, Arrest, Implantable cardioverter-defibrillator

J. Christian Hays, MD , Director of Cardiac Electrophysiology at St. Elizabeth Healthcare, performed the procedure on January 12, 2024.

Key Points: 
  • J. Christian Hays, MD , Director of Cardiac Electrophysiology at St. Elizabeth Healthcare, performed the procedure on January 12, 2024.
  • Implantable cardioverter-defibrillators (ICDs) are devices doctors implant in the upper chest to treat arrhythmias.
  • If it detects an irregular heart rhythm or one that's too fast, the device sends an electrical signal through the lead to the heart.
  • Learn more about cardiology services offered at St. Elizabeth Healthcare or contact us at 859-331-3353.

Biosense Webster Presents Late-Breaking Data from inspIRE and admIRE Clinical Trials at AF Symposium

Retrieved on: 
토요일, 2월 3, 2024
Fluoroscopy, Arrhythmia, Catheter ablation, Workflow, Hospital, Atrial tachycardia, Success, Platform, 3D, Kansas Day, Patient, Safety, PFA, Johnson & Johnson, Recurrence, Freedom, Cardiac electrophysiology, Atrium (heart), Atrial flutter, Risk, Atrial fibrillation, Pharmaceutical industry

IRVINE, Calif., Feb. 2, 2024 /PRNewswire/ -- Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTechi, announced 12-month results from the company-sponsored inspIRE study, "Predictors of Success for Pulmonary Vein Isolation with Pulsed Field Ablation (PFA) Using a Variable Loop Catheter with 3D Mapping Integration: Complete 12-month outcomes from inspIRE," presented as a late-breaking presentation at the 29th Annual International AF Symposium.1 Interim results from the company-sponsored admIRE study, titled "PFA Using a Variable Loop Circular Catheter with 3D Mapping Integration: Early Outcomes of the admIRE Study," were also shared in a late-breaking presentation.2

Key Points: 
  • The CARTO™ System enables an intuitive and reproducible workflow with real-time visualization and feedback mechanisms.
  • "Biosense Webster is committed to bringing forward a versatile, differentiated portfolio of PFA solutions designed to help electrophysiologists deliver safe, effective, and efficient cardiac ablation procedures," said Jasmina Brooks, President, Biosense Webster, Inc. "The encouraging outcomes from clinical trials with VARIPULSE™ fuel our excitement as we continue to deliver innovations to meet the diverse needs and ablation strategies required to successfully treat atrial fibrillation."
  • The inspIRE study evaluated the safety and effectiveness of the VARIPULSE™ Platform for the treatment of drug-refractory paroxysmal AFib in Europe and Canada.1 In the study, the primary effectiveness endpoint of acute pulmonary vein isolation and 12-month freedom from atrial arrhythmia recurrence (AFib, Atrial Tachycardia, or Atrial Flutter) was 75.6%.
  • Among participants receiving optimal PFA applications, 80% achieved the primary effectiveness endpoint.1 The study reported a low fluoroscopy time of 7.8 minutes, partly attributed to the integration of the VARIPULSE™ Platform to the CARTO™ 3 System.

Attune Medical® Announces Support of AF Symposium 2024

Retrieved on: 
수요일, 1월 17, 2024
Medical Devices, Health, FDA, Other Health, Radiology, Cardiology, Atrial fibrillation, Symposium, Hospital, Temperature, Multimedia, Arrhythmia, Poster, NCH Healthcare System, Freedom, Cardiac electrophysiology, Environment, Emerging technologies, De novo, Fluoroscopy, Safety, Esophagus, Radiofrequency ablation, Patient safety, Education, Liquor

Attune Medical®, a pioneer in the field of esophageal temperature management with its ensoETM® device, is providing significant support for the upcoming AF Symposium as part of the company’s corporate mission.

Key Points: 
  • Attune Medical®, a pioneer in the field of esophageal temperature management with its ensoETM® device, is providing significant support for the upcoming AF Symposium as part of the company’s corporate mission.
  • AF Symposium, scheduled for February 1-3 in Boston, Massachusetts, gathers the world's leading electrophysiologists to share, in a highly interactive environment, the latest advances in the treatment of atrial fibrillation.
  • (Photo: Business Wire)
    As part of its mission to support education and enhance patient outcomes, Attune Medical is the primary corporate sponsor of the AF Symposium EP Fellows’ Scholarship Program and the dedicated Interactive Educational Program for fellows on Saturday, February 3 from 4-8 p.m.
  • The AF Symposium Fellows’ Program offers a unique opportunity to engage with leaders in Cardiac Electrophysiology during this exclusive four-hour session.